GlassScriptPhysician profile
Scott David Peterson
NPI 1427008812
$5,654.60
in general payments reported to CMS, 2019-2025
39 companies · $788 in 2025
The $788 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $238 · 2020: $608 · 2021: $1,119 · 2022: $858 · 2023: $1,082 · 2024: $961 · 2025: $788.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,824 · Education: $6.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,824.26 |
| Education | $6.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $860.77 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Abbvie INC. | $758.75 | 2020-2025 | |
| Lilly USA, LLC | $538.71 | 2019-2024 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $485.09 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Merck Sharp & Dohme LLC | $424.67 | 2020-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Amgen INC. | $376.22 | 2019-2025 | Evenity, Repatha, Repatha |
| Astellas Pharma US INC | $352.64 | 2019-2025 | Veozah, Myrbetriq |
| Novo Nordisk INC | $320.05 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $205.98 | 2019-2025 | Shingrix, Arexvy |
| Pfizer INC. | $203.76 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $153.51 | 2020-2024 | Xarelto |
| Amarin Pharma, INC. | $130.62 | 2019-2021 | |
| Abbott Laboratories | $104.45 | 2021-2022 | |
| Organon LLC | $71.98 | 2021-2025 | Nexplanon |
| Bayer Healthcare Pharmaceuticals INC. | $66.09 | 2019-2023 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Peterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.